- Open Access
Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs
Orphanet Journal of Rare Diseases volume 17, Article number: 274 (2022)
Spinal muscular atrophy (SMA) is a rare degenerative neuromuscular disease, mostly occurring in infants and children, leading to muscle wasting and weakness, and premature death. Due to new developments of multiple disease-modifying treatments within the last years, the interest of research in patients affected by SMA increased steadily. However, the psychosocial situation of parents as informal caregivers is still rarely addressed.
This review aims to highlight quantitative and qualitative data about the psychosocial situation, caregiver burden, and needs of parents as informal caregivers for children and adolescents with SMA.
A systematic literature review was performed including quantitative and qualitative original studies focusing on different psychosocial aspects and outcomes for parents of children and adolescents < 21 years of age with SMA type I–IV (PROSPERO; registration number CRD42020219020). We searched the following databases in November 2020 with a research update in August 2021: MEDLINE, CINAHL, PsycINFO and Web of Science.
In total, 24 articles from 23 studies were selected for inclusion (15 quantitative studies, 7 articles from 6 qualitative studies, 2 mixed methods studies). The synthesis of included studies shows multiple sources of psychosocial burden for parents of children and adolescents affected by SMA: Most studies found reduced levels of quality of life, moderate to high levels of caregiver burden and distress, as well as physical and mental health symptoms. Further, findings indicate several unmet family needs regarding information, care coordination, treatment decisions, financial support, and adequate supportive care services.
Parents of children and adolescents with SMA face multiple sources of psychosocial stressors, caregiver burden and various unmet family needs. To unburden families, the needs of parents as caregivers should be included in integrated care paths for SMA to improve their psychosocial situation and thus their ability to care for their children and to treat or prevent physical and mental health problems due to overburdening. Future research should focus not only on quality of life and on caregiving-related burden but should also examine the clinical relevance of reported symptoms to support the implementation of adequate support services for families affected by SMA.
Spinal muscular atrophy (SMA) is a rare autosomal recessive neurodegenerative disease, caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation and leading to muscle wasting and proximal muscle weakness . With an incidence about one in 10 000 livebirths with a carrier frequency of one in 50, spinal muscular atrophy is one of the most common rare neuromuscular diseases and the primary genetic cause of deaths in infants [1, 2]. The severity of the disease is classified into clinical subtypes, which are correlated with the age of onset and the number of the remaining copies of the SMN2-gene:
SMA type I (Werdnig-Hoffmann disease) accounts for about 50–60% of all SMA cases. It is the most severe type and appears in children under the age of 6 months. Children affected by this type have hypotonia, flaccid paralysis, and are not able to sit unaided. Because of weakened muscles needed for respiration and swallowing, children with this type usually have a high risk of paradoxical breathing and respiratory infections. In addition to respiratory problems, some children with SMA type I have heart defects, both leading to an expected survival of 2 years without treatment or respiratory support [1,2,3,4].
SMA type II (30%) occurs in children between the age of seven and 18 months. Affected children usually learn to sit, but not to stand or walk. Kyphoscoliosis usually develops, requiring surgical or orthotic interventions. Like patients with type I, respiratory insufficiency is frequent, wherefore patients often die during adolescence .
Type III (Kugelberg-Welander disease, 10%) occurs after 18 months of live and shows profound symptom heterogeneity. Usually, it is characterised by limited motor neuron loss, the ability to walk (with support) and a normal life expectancy, but patients experience progressive impairments like scoliosis or joint contractures [1,2,3, 5]. Patients with type IV disease (1%) typically have onset of symptoms in adulthood, with mild motor impairment and without respiratory or nutritional problems .
To reliably diagnose SMA, patients with typical clinical features need to be tested for homozygous deletion or mutation of the SMN1 gene . This leads to delays in diagnosis, especially in SMA types with a later onset of symptoms . In order to prevent delays of diagnosis, inclusion of SMA in nationwide newborn screenings has been discussed and pilot tested in several countries for over a decade . Between 2018 and 2022, most states or provinces of the US, Canada, and Australia, as well as three European countries (Germany, Norway, and Belgium) started to screen newborns [8, 9].
Until a few years ago, standards of care for SMA included most notably palliative care, (non-)invasive ventilation, and gastrostomy for severely affected patients as well as scoliosis surgery and orthotic management for all SMA types [2, 4]. Within the past years, novel and promising disease-modifying medical treatment options (nusinersen [Spinraza®], authorised in 2017, onasemnogene abeparvovec-xioi [Zolgensma®], authorised in 2020 and risdiplam [Evrysdi®], authorised in 2021 for use in the European Union) have been successfully approved for clinical use in addition to the existing standards of care [10, 11]. Although those recently approved treatment options can reduce the mortality and severity of disease progression, curing SMA is still not possible and the long-term efficacy remains unclear, leaving ethical, medical, and financial implications for affected families unanswered [3, 10]. While pressure from regulatory authorities and the SMA community to include not only patients’ but also parents’ perspectives on the impact of new treatments on their quality of life in research increases [3, 12], the majority of studies investigating quality of life in SMA focuses on patients, using the parents’ perspective only for proxy-report [12,13,14]. A recent review by Messina and colleagues focusing on patient- and parent-oriented tools for quality of life, daily activities, and caregiver burden in SMA identified only nine of 36 SMA-specific studies, which included an outcome for parents (caregiver burden) . Existing studies on quality of life, economic and social burden in affected families show that most of the parents of children with SMA report a high financial burden (i.e., for assistive equipment), a high amount of caregiver hours per day (≥ 10 h), reduced working hours for paid work, and an impaired quality of life [15,16,17,18].
The literature on the impact of SMA on parents as informal caregivers implicates multiple sources of burden, as well as negative psychological, social, and economic effects for affected families. To the best of our knowledge, so far, no study has systematically examined and synthesised existing literature on the psychosocial impact of SMA in children and adolescents on their parents. Therefore, the aim of our study was to review qualitative and quantitative studies on caregiver burden, the psychosocial situation, and family needs of parents as informal caregivers of children and adolescents with SMA.
This systematic literature review was conducted and reported in accordance with the items of the PRISMA checklist for systematic reviews , details available as supplemental material (Additional file 1). The review protocol has been registered in PROSPERO (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020219020).
We searched the following electronic databases in November 2020 with a research update in August 2021: MEDLINE, CINAHL, PsycINFO and Web of Science. The primary search terms ‘spinal muscular atrophy’ and ‘SMA’ were combined with keywords addressing psychosocial- and mental health-related terms (e.g., ‘depress*’, ‘distress’, ‘quality of life’) and caregiver-related terms (e.g., ‘parent*’, ‘caregiv*’). Full search strings are available as supplemental material (Additional file 2). We also searched citations and references of included studies, and relevant reviews to identify further relevant literature.
To be included, studies had to meet the following criteria: published in a peer-reviewed journal, in English or German language, accessibility as full text, including children and adolescents aged 21 years or younger with a SMA diagnosis type I–IV, and at least one relevant psychosocial outcome/theme for parents or legal guardians as informal caregivers. In this context, we defined ‘psychosocial’ as ‘individual psychological and social aspects […] related to individual’s social conditions, mental and emotional health’ . Further, ‘caregiver burden’ was defined as ‘an individual’s subjective perception of overload in one or more of four perspectives: physical, psychological, social, and financial through the caregiving process‘ , with the addition of a recent concept analysis that includes not only subjective, but also objective aspects of caregiver burden . Studies were included when inclusion criteria regarding sample characteristics were met in at least 70% of one sample, or if results were reported separately for relevant study subsamples (e.g., SMA-subgroup out of more heterogenous samples or disease groups).
We excluded studies focusing on other diagnoses than SMA, reporting outcomes for SMA-patients only or samples of bereaved parents. Articles based on the same study sample were included if they reported different outcomes/themes.
The titles and abstracts of articles were screened by two independent raters (MB, LJ). Full texts were retrieved if title and abstract were of interest, or the eligibility was unclear. Studies, which seemed to meet the inclusion criteria at first, were mostly excluded because of missing psychosocial outcomes for parents (e.g., ), because the sample included only few cases of SMA (e.g., ), or because a large fraction of parents was deceased (e.g., ). For details of the study selection process, see Fig. 1.
Data extraction and quality assessment
Included studies were classified by their methodological approach: (1) quantitative design, (2) qualitative design. Mixed methods studies were classified in one of the two categories, depending on the methodological approach of their relevant psychosocial outcome/aspect. Data of included studies were extracted by two of the authors (MB and LJ) independently and included the following information: citation details, country, study aims, study design, recruitment period and strategy, study population, and the main results of psychosocial outcomes (quantitative) or themes (qualitative) for parents.
To evaluate the quality of included studies, two reviewers (MB and LJ) independently assessed more than 80% (20 of 24) of the included articles using the Mixed Method Appraisal Tool (MMAT) . The MMAT is a widely used instrument and has shown to be a sufficiently reliable and valid tool to appraise the methodological quality of qualitative, quantitative, and mixed methods studies . The assessment of the quality of included articles revealed a good interrater agreement of 86% (Additional file 3).
We performed a narrative analysis to synthesise the data from included articles . For quantitative studies, we reported psychosocial and caregiving-related burden according to operationalisations used by the original studies. For the synthesis of qualitative findings, we decided to report ‘caregiver burden’ primarily as subjective perception of burden regarding the caregiving situation, whereas other aspects (e.g., mental, or physical health symptoms, financial costs) will be reported separately.
Through database search, a total of 764 records were found with 303 being duplicates. From the review of the remaining 461 articles, 54 were selected for full text screening based on their title and abstract. After reviewing full texts, 24 articles from 23 studies were selected for inclusion (15 quantitative studies, 7 articles from 6 qualitative studies, 2 mixed methods studies, see Fig. 1). The reasons for the exclusion of the remaining 30 full texts were most notably the lack of a psychosocial outcome for parents (n = 12), case studies with less than five cases of SMA (n = 4), studies with a high proportion of bereaved parents (n = 4) or other conditions than SMA (n = 4). For details see Fig. 1.
We identified 15 quantitative studies and one mixed methods study, including at least one psychosocial outcome for caregivers [15,16,17, 29,30,31,32,33,34,35,36,37,38,39,40,41]. For study details, see Table 1. Seven of 16 studies used parts of the same three study samples but the majority of participants in those samples were not identical and, hence, were included in our analyses as separate studies [15,16,17, 36,37,38,39]. Most studies were conducted in Europe and in the USA.
Most studies focused on affected families or patients and parents equally [29, 31, 37,38,39,40]. Five studies focused primarily on caregiver outcomes [15, 32, 33, 36, 41] and four studies assessed patients’ perspectives but, additionally, reported outcomes for parents [16, 17, 30, 34]. The majority of studies were cross-sectional, only three studies used a longitudinal design with two to three time points [34, 38, 41]. Sample sizes varied between n = 12 and n = 962 participants. No study was published before the year 2000, more than 80% were published within the last 5 years.
In almost all of the included studies, the parents were the informal caregivers of affected children and adolescents, only three studies (19%) also reported on grandparents [29, 30, 40]. In studies reporting the parents’ sex (n = 10) and age (n = 8), participants were mostly mothers as primary caregivers (44–100%). Parents’ mean age was 39–41 years in the majority of the studies (63%).
Mostly, children and adolescents included in the studies were diagnosed with SMA type II (38–75% of children and adolescents), two studies only included children and adolescents with SMA type I [30, 34]. Children and adolescents in studies including SMA subtypes I-III generally had a higher mean age than children and adolescents in studies including only type I patients (M = 6.1–12.7 vs. M = 3.0 years), whereas the sex ratio of children and adolescents was approximately balanced in most studies.
Three studies reported nusinersen and one study reported nusinersen, Zolgensma® or risdiplam as medical treatment for affected children and adolescents.
Most studies compared families within SMA subtypes (type I–III) and/or different status of medical interventions (e.g., receiving nusinersen, spinal surgery) [38,39,40]. Other studies compared affected families in different countries [15, 17], to healthy controls [30, 36, 37], or to families affected by other diseases [33, 37]. Further, three studies compared pre- and post-measurements before and after the start of medical treatment [34, 38, 41] and/or psychological intervention [34, 38, 41], one study compared parents of affected children and adolescents versus adult patients , and another study did not compare participants at all .
Psychosocial and burden-related outcomes for parents were: (health-related) quality of life (n = 10), caregiver burden (n = 7), caregiver time, (indirect) costs for families, parental stress, anxiety or depression symptoms, social support, coping (n = 2) as well as family needs, and satisfaction (n = 1). All included measurements were conducted through self-assessment tools.
(Health-related) quality of life
The most reported outcome for parents was (health-related) quality of life, with 63% (10 of 16) of studies reporting on this measure. Four of ten studies [33, 38,39,40] used the PedsQL™ Family Impact Module , three [16, 17, 35] used the EuroQol EQ-5D-5L , two [31, 41] used the CarerQoL  and one  used self-developed questions.
Reduced quality of life was found in parents (a) with mental (46–84%) or physical (78%) health symptoms of their own [31, 35], (b) with financial problems due to care tasks (78%) , (c) of children and adolescents with more severe SMA subtypes (I–II) [33, 35, 38,39,40], and (d) shortly after a positive screening result for SMA . Further, parents of children and adolescents with SMA were more likely to have lower quality of life than the general population  or parents of children and adolescents with other neuromuscular disorders , and if they lived in France instead of the UK or Germany .
Higher levels of quality of life were reported to be more likely in parents of children and adolescents with SMA type III [33, 35, 38,39,40], and if affected children and adolescents received spinal surgery , exercise training, or had a multidisciplinary team management for their treatment . Nusinersen treatment was found to be either beneficial  or detrimental  for parental quality of life. One study, which used self-developed questions with semantic rating scales to measure parental quality of life, found all parents to report their lives satisfying and rewarding, even though 66% reported to have a rather hard life and 54% reported to feel tied down .
Of included studies which used caregiver burden as outcome (7 of 16), four [15,16,17, 29] used the Zarit Burden Interview (ZBI) , two [32, 35] used the Caregiver Strain Index (CSI)  and one  used self-developed questions.
In included studies using caregiver burden as an outcome, on average, most parents reported mild to moderate burden [15,16,17, 29], or high levels of stress due to their caregiving situation [32, 35]. The most frequently reported negative effects of caregiving on parents were sleep disturbances, physical or mental health symptoms of their own, changes in personal plans, work adjustments, and financial problems [32, 35]. One study with self-developed questions found, that although the effort to raise a child with SMA was higher than for parents with healthy children and adolescents, the feeling of burden was not . One study found differences in caregiving-related burden between SMA subtypes, with the highest burden on parents of patients with type II . Another study did not find any burden-related differences between parents of children and adolescents with different SMA subtypes .
Four of 16 included studies used caregiver time of parents as an outcome [15,16,17, 35]. Caregiver time was mostly assessed using the recall method  to estimate daily care activities and needed time per activity with a maximum of 16 h per day for all care activities (e.g. ).
Included studies found an average caregiver time of at least five h per day in a Canadian sample  and up to 12.5 h per day in samples from the UK [15, 16], with patients suffering from more severe SMA subtypes (I–II) requiring more time (> 10 h per day) than type III patients (e.g. [15, 17]). Further, one study reported that, in addition to the main caregiver, averagely two other people were involved in the informal care of a patient with SMA and 47% received additional caregiving support by professional paid carers .
(Indirect) costs for families
Three included studies reported (indirect) costs for families that took care of a child with SMA [16, 17, 31]. All of them used self-delevoped approaches to estimate healthcare costs for affected families. Total healthcare costs varied across countries, with similar average costs per year for Australia ($33,000) , Spain (€33,721) , and France (€32,042) and higher costs for Germany (€51,983) and the UK (€54,295) . All studies reported that informal care costs and loss of income, both borne by affected families, constituted substantial proportions of total healthcare costs (20–68%). Two of three studies reported extensive use of informal care, especially in families with more severe SMA types (I–II), and that families with children and adolescents suffering from SMA type II had to bear the highest average costs compared to type I and III [16, 31], although total healthcare costs for type I were reported to be even higher .
Two studies found significantly higher stress rates in parents of children and adolescents with SMA compared to parents of healthy controls [36, 37]. Within families affected by SMA, higher stress rates were found in families with less social support, more behaviorual problems of children and adolescents, and a higher degree of the child’s disability as well as for SMA type I and II compared to type III . One study comparing parents of children and adolescents with different neuromuscular diseases, including SMA, reported that 37% of parents within all disease groups experienced high stress levels with significantly reduced quality of life and family functioning compared to parents with lower stress levels .
Two studies, using parts of the same study sample, assessed family coping with the Family Crisis Orientated Personal Evaluation Scale (F-COPES), reporting equal coping abilities for families affected by SMA and families with healthy children and adolescents [36, 37].
The German questionnaire on social support (Fragebogen zur sozialen Unterstützung, F-SOZU) was used in two studies, using parts of the same study sample, to measure levels of perceived social support [36, 37]. One study reported significantly lower levels of perceived social support in families affected by SMA , and one study found equal levels compared to families with healthy children and adolescents .
Anxiety and depression symptoms
Two studies assessed anxiety [32, 34], one of them additionally measuring depressive symptoms, using the State Anxiety Inventory (STAI)  and the Hospital Anxiety and Depression Scale (HADS) . One study reported high anxiety and depressive symptoms in 53% of mothers of children and adolescents with SMA, indicating slightly higher symptoms compared to mothers of adult patients with SMA . One study measuring anxiety levels in parents shortly before nusinersen administration via lumbar punction (LP) of affected children and adolescents showed mild anxiety symptoms which decreased over time after the introduction of a self-developed psychological intervention .
Additionally, one study using the subscale ‘anxiety/depression’ of the EQ-5D-5L reported that 65% of caregivers in a large Canadian sample showed at least some degree of anxiety or depressive symptoms with higher rates for parents of type I–II patients (69–74%) compared to those of type III patients (46%) .
Family needs were assessed in one study from Turkey  using the Family Needs Assessment Tool (FNAT) . Most parents reported needs for the subscales ‘information’ (66%), especially about institutions the child could benefit from (97%), ‘financial needs’ (46%), and ‘general support and social service’ (36%) like the need for someone to talk to about family problems (50%).
One study comparing mothers of children and adolescents with adults with SMA assessed satisfaction with participation in daily life (e.g., vocational and leisure activities), using the Utrecht Scale of Rehabilitation-Participation (USER-P) . Although all mothers reported to be (very) satisfied about their activities, multivariate analysis identified participation in social/leisure activities as a significant predictor for caregiver burden, depression and anxiety symptoms, and satisfaction.
Of the included studies, seven articles of six qualitative studies [56,57,58,59,60,61,62,63] and one mixed method study  focused at least on one psychosocial aspect of the caregivers’ experience with paediatric SMA (Table 2). Two articles shared the same study sample but had a different psychosocial focus and were therefore both included [59, 60]. Most studies (4 of 7) were conducted in Australia and in the USA, two studies are from Europe, and one is from Taiwan. Three articles focused on treatment decisions and parents’ views on new therapy options [57, 58, 62], three other articles concentrated mainly on the experience of caregiving and life with SMA more generally [56, 59, 63], and two articles focused on the experience of receiving the child’s diagnosis [60, 64]. Sample sizes varied from n = 7 to n = 64 participants. All articles were published after 2015 with data collected between 2010 and 2018.
As in the included quantitative studies, in all but one article which also included grandparents , informal caregivers were parents of affected children and adolescents. The majority of interviewees was female (53–100%). Age, family status and employment were not reported in most studies (57–71%).
For children and adolescents in included studies, SMA subtypes varied across samples, with two of seven studies including SMA type I–III, whereas the rest focused on one or two of the subtypes I–III. The age of children and adolescents ranged between < 1 year and 25 years, with > 90% being younger than 18 years. The sex of children and adolescents was rarely reported (29% of studies). In three studies, children and adolescents received medical treatment (nusinersen).
Qualitative findings of included articles could be divided into two main categories of psychosocial effects on caregivers: (1) family needs, caregiver burden, and psychosocial impact on parents as well as (2) experiences in the course of treatment (first symptoms, receiving the diagnosis, experiences with treatment and decision making).
Family needs, caregiver burden, and psychosocial impact on parents
The most prominent topic in the included articles (5 of 8 studies) was different kind of family needs. Parents mostly reported the need for information [56, 57, 62,63,64]. Even though many parents saw their child’s physician as the main source of information about the disease, they mostly did not feel sufficiently informed, sometimes left alone, and reported using the internet, social media groups, and support organisations as supplementary sources [56, 57, 62, 64]. Several articles reported the parents’ feeling of trying to close an information gap, which was reported to be time-consuming and frustrating because of difficult access to information and complexity [56, 57, 62]. The wish for information was not limited to information about the disease and treatment options, but also expressed in regard to supportive care services such as financial assistance, access to equipment, paid care, schooling etc. [56, 57, 62].
Further, some parents felt more experienced with the disease than the child’s physician, reporting the need for better educated health care professionals [62,63,64]. They experienced unawareness and lack of information on the healthcare professionals’ side, leading to ignorance toward first symptoms, delay of diagnosis, potentially misleading information about the disease and controversies with parents about testing and treatments [62, 64, 65].
Besides the need for information and the awareness of healthcare professionals for SMA, parents in several articles expressed their need for coordinated and integrated care, including not only medical treatment, but also psychological and practical care support. Parents often reported to feel left alone after the diagnosis, struggling to find the right solutions for their child, because of complex and time-consuming navigation through the health care and support system due to lack of clearly defined and integrated support pathways [56, 57, 62].
Further, families reported the need for adequate supportive care services, like specific schooling or services for children and adolescents with physical disabilities, but without cognitive impairment [56, 62]. Parents in one Australian study additionally addressed the need for financial support, because government financial assistance only partially covered their costs for non-medical care (e.g., equipment), so that most families were additionally reliant on support from charities and fundraising .
Caregiver burden was reported by most parents in several articles (3 of 8). One central aspect was prioritising the child’s need ahead of own care or the needs and wants of other family members. This reached from constant awareness of the child to be moved or adjusted day and night, sacrificing leisure time to the extent of moving with the family and quitting jobs for adequate schooling for the affected child [56, 59, 60].
In addition, parents reported to be burdened by never-ending care tasks, causing fatigue, exhaustion, and severe lack of sleep due to limited leisure time [56, 59, 60]. Financial burden due to high care costs and loss of income, as well as uncertainty about the future because of the child’s disease progression, and difficult treatment choices were also addressed in two studies [56, 60].
The psychosocial impact of SMA on parents of affected children and adolescents included own (mental) health problems like back pain due to care tasks, depression, anxiety, and high levels of distress and emotional burden, uncertainty about the future because of the child’s disease progression, a narrowing of social networks due to limited leisure time or the child’s immobility, as well as conflicts and changes in family dynamics [56, 60, 63]. Further, stresses on family finances and limited employment and career opportunities due to caregiving were reported as negative effects by some parents .
Experiences in the course of treatment
Three articles concentrated specifically on the parents’ experience of searching for and receiving the diagnosis of their child [60, 63, 64]. Although many parents described an early feeling that something was wrong with their child, most of them received the diagnosis with a delay due to trusting false judgements of physicians, consulting many specialists before receiving the correct diagnosis or long distances to and waiting times for appointments and test results.
Parents mostly experienced the way to receive the diagnosis as an (emotionally) protracted journey accompanied by feelings of denial, stress, anxiety, and worry [60, 63, 64]. When receiving the diagnosis, parents were mostly in a state of shock, reporting numbness, denial, worry and increasing sadness [60, 63, 64], sometimes resulting in long term grief and depression due to confrontation with the premature death of the child and lost expectations for a normal life . Further, some parents reported that the insensitive and unhelpful style of communication by the child’s physician made their situation even worse .
Three articles focused on parents’ expectations [57, 58, 62], two of them additionally on decision making [57, 58] and one of them concentrated on experiences with nusinersen as the first approved disease-modifying drug for SMA .
Most parents reported that hope to change the child’s disease progression, life expectancy and quality of life was the most central expectation for nusinersen treatment [57, 58, 62]. Further, parents expressed their wish for their child to manage the disease and live a more independent and longer life.
In spite of positive expectations for medical treatment options, concerns were also reported: besides the concern of permanent cost takeover for treatments, some parents worried about treatment complications and side effects, that the treatment might be too intensive for their child and would cause pain and limited quality of life as well as long-term suffering and greater emotional pain due to the child’s increasing awareness of the disease as it is living longer [57, 58].
In regard to decision making, besides hope for improvement of the child’s health situation and quality of life, the relationship with the child’s treatment team was the most important factor for parents to ease a final treatment decision . Parents reported to feel supported in treatment decisions if they (a) got sufficient information, (b) had a good, informative relationship with physicians who stayed neutral toward the parents’ decision, and (c) were familiar with the treatment process.
Parents’ perception of treatment effects of nusinersen can be summarised as a reassuring effect because the clinical situation of most patients stabilised after treatment enrolment, giving them a radical change of outlook from a very limited life expectancy to new perspectives and hope for their child’s future .
The aim of this study was to systematically review the existing quantitative and qualitative literature on the psychosocial situation, caregiver burden, and family needs of parents as informal caregivers of children and adolescents with SMA. Results indicate that the parents’ perspective has been studied in several geographic settings and populations with a growing interest especially within the last 10 years.
By covering a broad variety in study focuses, sample sizes, outcome measurements and study quality, our review of included studies delivers a deeper and broader understanding of the psychosocial situation of parents as informal cargivers of children and adolescents affected by SMA.
Parents in the included studies reported that taking care of their chronically ill child can be fulfilling and satisfying despite the high caregiving effort for families . However, results demonstrate that parents of children and adolescents with SMA experience multiple burdens and reduced quality of life, moderate to high levels of caregiver burden and stress, and often report unmet family needs (e.g., information needs, care integration and management, financial support, adequate supportive care services). Further, parents often prioritise their child’s needs over their own or over those of other family members and spend many hours per day and night to take care of their child. This is mostly associated with sacrificing leisure time and social contacts at the cost of their own quality of life as well as physical and mental health. In addition to the time-consuming day-to-day care tasks, parents spend much time and energy on closing information gaps and navigating through the healthcare and support system, trying to find suitable solutions for their child, e.g., regarding care, financial support, or adequate schooling.
Especially parents of children and adolescents with more severe SMA subtypes (I–II) are strongly affected by negative consequences of the caregiving situation: besides the necessity to spend more time on caregiving and to bear higher healthcare costs (e.g., for equipment), parents of children and adolescents with subtypes I–II are more likely to face difficult treatment decisions, ethical concerns, the premature death, or the palliative situation of their child [67,68,69,70]. These aggravating circumstances in patients affected by SMA type I-II might be associated with higher caregiver burden, reduced rates of quality of live and (mental) health problems in parental caregivers compared to parents of patients with SMA type III.
Even though not all parents might be affected by SMA in a way that calls for additional support, the findings of the included studies indicate that receiving the SMA diagnosis can cause post-traumatic symptoms and that a substantial proportion of parents experience physical and mental health problems in the course of SMA due to the caregiving situation. These findings are in line with reviews focusing on the psychosocial situation of parents with chronically ill children and adolescents with other rare diseases (e.g., cystic fibrosis, paediatric cancer) and indicate a strong recommendation for parents to receive early and ongoing assessment of their mental health needs with access to appropriate interventions to optimise parent, child, and family well-being [71,72,73].
Further, the vast majority of parents as primary caregivers in the included studies were mothers (44–100%). Even though this might reflect the reality of most families in which caregivers of children and adolescents with rare and/or life-limiting illnesses continue to follow the stereotypes whereby women are the predominant caregivers  and men are the predominant breadwinners , studies comparing mothers and fathers as caregivers found different levels of mental health symptoms, perceived burden, social support, and different supportive care needs [74, 75]. Therefore, our findings might be primarily applicable to mothers of children and adolescents with SMA, indicating that future research is needed to address gender differences in caregiver burden and supportive care needs between mothers and fathers of children and adolescents affected by SMA.
Due to the novelty of disease-modifying therapy options for SMA, most of the included studies were conducted before the authorisation of those therapies, leaving the question unanswered, how they could change the course of the disease and the psychosocial situation of families with children and adolescents affected by SMA. The few studies included in our review integrating parents’ experiences with new treatment options indicate that the child’s physician’s or treatment team’s expertise as well as the relationship between families and healthcare professionals might become even more important to support and help parents with difficult treatment decisions [57, 58]. The importance of the physician-parent relationship and the physician’s expertise also seems to play an essential role in the communication of diagnosis  as well as in palliative care decisions [69, 70]. Especially the communication of diagnosis might cause substantial emotional burden in parents of children and adolescents affected by SMA if performed in an insensitive or uninformed manner .
Although the review of included studies provides a deeper understanding of the caregiving situation in paediatric SMA, it also exhibits several limitations future research should try to address: Firstly, most of the included quantitative studies did not include a matched control group or SMA-specific measurements for psychosocial outcomes. Thus, as well as due to partly small sample sizes of some studies, it is difficult to assess the actual extent of caregiver burden.
Secondly, there exists a broad range of healthcare costs, access to newborn screening and disease-modifying treatments across countries, SMA subtypes and time points of data collection in the included studies, which impedes general conlusions about the caregiving situation in paediatric SMA. Although studies comparing healthcare costs and quality of life in caregivers across several European countries found higher quality of life in countries spending more money per child in healthcare costs (UK and Germany) , the healthcare situation in SMA is complex and rapidly changing, and therefore should be highlighted by considering more disease- and treatment-specific information in future studies.
Thirdly, essential descriptive data about caregivers was missing in most studies, making comparisons across studies difficult, and indicating that caregivers and their situation are not the main focus of the existing literature. The latter is also supported by the fact that only two of the 16 included studies using quantitative outcomes included measurements to assess clinically relevant psychological symptoms, hence neglecting the assessment of the potential need for psychological support for most caregivers despite findings of moderate to high general burden.
Existing quantitative and qualitative literature about the psychosocial situation of parents as informal caregivers in paediatric SMA show multiple sources of burden including reduced levels of quality of life, moderate to high levels of stress and caregiver burden, as well as physical and mental health symptoms, especially for parents of children and adolescents affected by SMA type I and II. Further, studies show several unmet family needs regarding information, decision making, care integration, financial support, and supportive care services. To reduce the burden on families, healthcare policies should ensure sufficient financial support and adequate supportive care services, not only for affected children and adolescents, but also for parents, as well as care integration for affected families. Healthcare professionals should be educated to identify SMA-related symptoms, receive communication training for delivering life-threatening diagnoses and work in multiprofessional teams to address not only medical information needs, but also other psychosocial needs of families (e.g., psychosocial support). Further research should concentrate not only on quality of life and caregiving-related burden, but also examine the clinical relevance of symptoms reported by parents in order to prevent and, if need be, treat mental disorders due to overburdening.
Availability of data and materials
The data generated and analyzed in this study are included in the supplementary material files.
Spinal muscular atrophy
Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120–33.
Borell S, Pechmann A, Kirschner J. Spinal muscular atrophy. Diagnosis and therapy. Monatsschrift Kinderheilkund. 2015;163(12):1293–301.
Messina S. New directions for SMA therapy. J Clin Med. 2018;7(9):251.
Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443–52.
Aartsma-Rus A, Balabanov P, Binetti L, Haas M, Haberkamp M, Mitchell J, et al. Stakeholder collaboration for spinal muscular atrophy therapy development. Lancet Neurol. 2017;16(4):264.
Pera MC, Coratti G, Berti B, D’Amico A, Sframeli M, Albamonte E, et al. Diagnostic journey in spinal muscular atrophy: is it still an odyssey? PLoS ONE. 2020;15(3):e0230677.
Ross LF, Clarke AJ. A historical and current review of newborn screening for neuromuscular disorders from around the world: lessons for the United States. Pediatr Neurol. 2017;77:12–22.
Hale K, Ojodu J, Singh S. Landscape of Spinal muscular atrophy newborn screening in the United States: 2018–2021. Int J Neonatal Screen. 2021;7(3):33.
SMA NBS Alliance. european alliance for newbornscreening in spinal muscular atrophy n.d. https://www.sma-screening-alliance.org/. Accessed 19 May 2022
Vu-Han T-L, Weiß C, Pumberger M. Novel therapies for spinal muscular atrophy are likely changing the patient phenotype. Spine J. 2020;20(12):1893–8.
Cartwright MS, Upadhya S. Selecting disease-modifying medications in 5q spinal muscular atrophy. Muscle Nerve. 2021;64(4):404–12.
Messina S, Frongia AL, Antonaci L, Pera MC, Coratti G, Pane M, et al. A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy. Neuromuscul Disord. 2019;29(12):940–50.
Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res. 2018;27(12):3087–94.
Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmüller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: a systematic review. Eur J Paediatr Neurol. 2019;23(3):347–56.
Aranda-Reneo I, Pena-Longobardo LM, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano EF, et al. The burden of spinal muscular atrophy on informal caregivers. Int J Environl Res Pub Health. 2020;17(23):8989.
López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):141.
Peña-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E, et al. The economic impact and health-related quality of life of spinal muscular atrophy. An analysis across Europe. Int J Environ Res Pub Health. 2020;17(16):5640.
Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1):58.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
Vizzotto ADB, de Oliveira AM, Elkis H, Cordeiro Q, Buchain PC. Psychosocial characteristics. In: Gellman MD, Turner JR, editors. Encyclopedia of behavioral medicine. New York: Springer; 2013. p. 1578–80.
Chou K-R. Caregiver burden: a concept analysis. J Pediatr Nurs. 2000;15(6):398–407.
Liu Z, Heffernan C, Tan J. Caregiver burden: a concept analysis. Int J Nurs Sci. 2020;7(4):438–45.
Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the cure SMA community update survey. Orphanet J Rare Dis. 2020;15(1):217.
Boardman FK. Experience as knowledge: disability, distillation and (reprogenetic) decision-making. Soc Sci Med. 2017;191:186–93.
Murrell DV, Crawford CA, Jackson CT, Lotze TE, Wiemann CM. Identifying opportunities to provide family-centered care for families with children with type 1 spinal muscular atrophy. J Pediatr Nurs. 2018;43:111–9.
Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers. Educ Inf. 2018;34(4):285–91.
Pace R, Pluye P, Bartlett G, Macaulay AC, Salsberg J, Jagosh J, et al. Testing the reliability and efficiency of the pilot mixed methods appraisal tool (MMAT) for systematic mixed studies review. Int J Nurs Stud. 2012;49(1):47–53.
Dixon-Woods M, Agarwal S, Jones D, Young B, Sutton A. Synthesising qualitative and quantitative evidence: a review of possible methods. J Health Serv Res Policy. 2005;10(1):45–53.
Acar AE, Saygi EK, Imamoglu S, Ozturk G, Unver O, Ergenekon P, et al. The burden of primary caregivers of spinal muscular atrophy patients and their needs. Turkish Archives of Pediatrics. 2021;56(4):366–73.
Bach JR, Vega J, Majors J, Friedman A. Spinal muscular atrophy type 1 quality of life. Am J Phys Med Rehabil. 2003;82(2):137–42.
Chambers GM, Settumba SN, Carey KA, Cairns A, Menezes MP, Ryan M, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020;95(1):e1–10.
Cremers CH, Fischer MJ, Kruitwagen-van Reenen ET, Wadman RI, Vervoordeldonk JJ, Verhoef M, et al. Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy. Neuromuscul Disord. 2019;29(4):321–9.
Ho MHT, Lang R, Ip YT, Zhi H, Wong WHS, Chan SHS. The impact of paediatric neuromuscular disorders on parents’ health-related quality of life and family functioning. Hong Kong J Paediatr. 2021;26(1):14–20.
La Foresta S, Faraone C, Sframeli M, Vita GL, Russo M, Profazio C, et al. Intrathecal administration of nusinersen in type 1 SMA: successful psychological program in a single Italian center. Neurol Sci. 2018;39(11):1961–4.
McMillan HJ, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553–68.
von Gontard A, Rudnik-Schöneborn S, Zerres K. Stress and coping in parents of children and adolescents with spinal muscular atrophy. Klin Padiatr. 2012;224(4):247–51.
von Gontard A, Backes M, Laufersweiler-Plass C, Wendland C, Lehmkuhl G, Zerres K, et al. Psychopathology and familial stress: comparison of boys with Fragile X syndrome and spinal muscular atrophy. J Child Psychol Psychiatr. 2002;43(7):949–57.
Weaver MS, Yuroff A, Sund S, Hetzel S, Halanski MA. Quality of life outcomes according to differential nusinersen exposure in pediatric spinal muscular atrophy. Children-Basel. 2021;8(7):604.
Weaver MS, Hanna R, Hetzel S, Patterson K, Yuroff A, Sund S, et al. A Prospective, crossover survey study of child- and proxy-reported quality of life according to spinal muscular atrophy type and medical interventions. J Child Neurol. 2020;35(5):322–30.
Yao M, Ma Y, Qian R, Xia Y, Yuan C, Bai G, et al. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis. 2021;16(1):7.
Kariyawasam DST, D’Silva AM, Vetsch J, Wakefield CE, Wiley V, Farrar MA. We needed this: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. Eclinicalmedicine. 2021;33:100742.
Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PEDSQL family impact module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res: Int J Qual Life Asp Treat, Care Rehabilit. 2011;20(10):1727–36.
Brouwer WBF, van Exel NJA, van Gorp B, Redekop WK. The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Qual Life Res. 2006;15(6):1005–21.
Ho H-M, Tseng Y-H, Hsin Y-M, Chou F-H, Lin W-T. Living with illness and self-transcendence: the lived experience of patients with spinal muscular atrophy. J Adv Nurs. 2016;72(11):2695–705.
Awa HDM, Mvondo RMN, Nguefack S, Messanga CB, Ndombo POK. Rare disease and their clinical oral manifestations in two hospitals in Yaounde. Pan Afr Med J. 2019;32:195–195.
Bédard M, Molloy DW, Squire L, Dubois S, Lever JA, O’Donnell M. The Zarit Burden Interview: a new short version and screening version. Gerontologist. 2001;41(5):652–7.
Robinson BC. Validation of a caregiver strain index. J Gerontol. 1983;38(3):344–8.
Van den Berg B, Spauwen P. Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving. Health Econ. 2006;15(5):447–60.
Friedrich WN, Greenberg MT, Crnic K. A short-form of the questionnaire on resources and stress. Am J Mental Defic. 1983.
Berry JO, Jones WH. The parental stress scale: Initial psychometric evidence. J Soc Pers Relat. 1995;12(3):463–72.
Spielberger CD, Gorsuch R, Lushene R, Vagg P, Jacobs G. State-trait anxiety inventory. Palo Alto: Mind Garden; 1983.
Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J (Clin Res Ed). 1986;292(6516):344.
Rawlins PS, Rawlins TD, Homer M. Development of the family needs assessment tool. West J Nurs Res. 1990;12(2):201–14.
Van der Zee CH, Priesterbach AR, van der Dussen L, Kap A, Schepers VP, Visser-Meily J, et al. Reproducibility of three self-report participation measures: the ICF measure of participation and activities screener, the participation scale, and the utrecht scale for evaluation of rehabilitation-participation. J Rehabil Med. 2010;42(8):752–7.
Farrar MA, Carey KA, Paguinto SG, Chambers G, Kasparian NA. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. Bmj Open. 2018;8(5):e020907.
Farrar MA, Carey KA, Paguinto SG, Kasparian NA, De Abreu LR. "The Whole game is changing and You’ve got hope”: Australian perspectives on treatment decision making in spinal muscular atrophy. Patient. 2020;13(4):389–400.
Kiefer P, Kirschner J, Pechmann A, Langer T. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study. Orphanet J Rare Dis. 2020;15(1):194.
McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68.
Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.
Agra Tuñas MC, Sánchez Santos L, Busto Cuiñas M, Rodríguez NA. Spinal muscular atrophy and respiratory failure How do primary care pediatricians act in a simulated scenario? An Pediatr (Barc). 2015;83(5):336–40.
Van Kruijsbergen M, Schroder CD, Ketelaar M, Van Der Pol W, Cuppen I, Van Der Geest A, et al. Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy. Dev Med Child Neurol. 2021;63(7):816–23.
Yang B-H, Mu P-F, Wang W-S. The experiences of families living with the anticipatory loss of a school-age child with spinal muscular atrophy-The parents’ perspectives. J Clin Nurs. 2016;25(17–18):2648–57.
Lawton S, Hickerton C, Archibald AD, McClaren BJ, Metcalfe SA. A mixed methods exploration of families’ experiences of the diagnosis of childhood spinal muscular atrophy. Eur J Hum Genet. 2015;23(5):575–80.
Choi HB, Liles EE. Adapting child-centered play therapy for children with spinal muscular atrophy. Int J Play Ther. 2018;27(4):205–14.
Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh W. The experiences of individuals and families affected by spinal muscular atrophy (SMA) and their views on living with SMA. Neuromuscul Disord. 2015;25:S191–2.
García-Salido A, de Paso-Mora MG, Monleón-Luque M, Martino-Alba R. Palliative care in children with spinal muscular atrophy type I: what do they need? Palliat Support Care. 2015;13(2):313–7.
Agosto C, Salamon E, Divisic A, Benedetti F, Giacomelli L, Shah A, et al. Do we always need to treat patients with spinal muscular atrophy? A personal view and experience. Orphanet J Rare Dis. 2021;16(1):78.
Hully M, Barnerias C, Chabalier D, Le Guen S, Germa V, Deladriere E, et al. Palliative care in SMA type 1: a prospective multicenter french study based on parents’ reports. Front Pediatr. 2020;8:4.
Chabrol B, Desguerre I. Ethical aspects in the care of a child with infantile spinal muscular atrophy (SMA). Arch Pediatr. 2020;27(7s):7s50–3.
Kearney JA, Salley CG, Muriel AC. Standards of psychosocial care for parents of children with cancer. Pediatr Blood Cancer. 2015;62(S5):S632–83.
Boettcher J, Boettcher M, Wiegand-Grefe S, Zapf H. Being the pillar for children with rare diseases: a systematic review on parental quality of life. Int J Environ Res Pub Health. 2021;18(9):4993.
Daly C, Ruane P, O’Reilly K, Longworth L, Vega-Hernandez G. Caregiver burden in cystic fibrosis: a systematic literature review. Ther Adv Respir Dis. 2022;16:17534666221086416.
Schneider M, Steele R, Cadell S, Hemsworth D. Differences on psychosocial outcomes between male and female caregivers of children with life-limiting illnesses. J Pediatr Nurs. 2011;26(3):186–99.
Nicholas DB, Beaune L, Barrera M, Blumberg J, Belletrutti M. Examining the experiences of fathers of children with a life-limiting illness. J Soc Work End Life Palliat Care. 2016;12(1–2):126–44.
Open Access funding enabled and organized by Projekt DEAL. The authors received no financial support for the research, authorship, and/or publication of this article.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. Table with PRISMA 2020 checklist.
. Electronic database search strategy for MEDLINE, CINAHL, PsycINFO and Web of Science.
Table with quality assessment of articles reporting a psychosocial outcome/aspect for parents of children with SMA using the MMAT.
About this article
Cite this article
Brandt, M., Johannsen, L., Inhestern, L. et al. Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs. Orphanet J Rare Dis 17, 274 (2022). https://doi.org/10.1186/s13023-022-02407-5
- Spinal muscular atrophy
- Caregiver burden
- Rare disease
- Family needs
- Quality of life
- Literature review